Testing effectiveness (Phase 2)Ended earlyNCT01434472
What this trial is testing
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
Who this might be right for
Post-Transplant Lymphoproliferative DisorderRecurrent Adult Diffuse Large Cell LymphomaRecurrent B-Cell Non-Hodgkin Lymphoma+4 more
Fred Hutchinson Cancer Center 20